Get the Stockscreener App
3.3364
2.98%
0.0964
Neuphoria Therapeutics Inc stock is traded at $3.3364, with a volume of 16,467.
It is up +2.98% in the last 24 hours and down -11.74% over the past month.
Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.
See More
Previous Close:
$3.24
Open:
$3.25
24h Volume:
16,467
Relative Volume:
1.00
Market Cap:
$18.05M
Revenue:
$15.00M
Net Income/Loss:
$2.71M
P/E Ratio:
2.6219
EPS:
1.2725
Net Cash Flow:
$-2.89M
1W Performance:
-0.41%
1M Performance:
-11.74%
6M Performance:
-28.25%
1Y Performance:
-80.65%
1-Day Range:
$3.25
$3.42
1-Week Range:
$3.24
$3.49
52-Week Range:
$3.19
$17.90
Neuphoria Therapeutics Inc Stock (NEUP) Company Profile
Name
Neuphoria Therapeutics Inc
Sector
Industry
Phone
781-439-5551
Address
100 SUMMIT DR, BURLINGTON
Compare NEUP vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NEUP
Neuphoria Therapeutics Inc
|
3.3364 | 18.05M | 15.00M | 2.71M | -2.89M | 1.2725 |
VRTX
Vertex Pharmaceuticals Inc
|
508.71 | 128.94B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
238.63 | 95.27B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
799.98 | 82.36B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
855.28 | 53.79B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.53 | 42.37B | 5.76B | 514.49M | 1.10B | 4.4813 |
Neuphoria Therapeutics Inc Stock (NEUP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-28-23 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Sep-28-23 | Reiterated | Maxim Group | Buy |
| Jan-10-22 | Initiated | Berenberg | Buy |
| Jan-10-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-10-22 | Initiated | Evercore ISI | Outperform |
| Jan-10-22 | Initiated | H.C. Wainwright | Buy |
View All
Neuphoria Therapeutics Inc Stock (NEUP) Latest News
Latigo Biotherapeutics, Inc. Common Stock (LTGO) Earnings Reports & Dates - FXEmpire
Neuphoria to Be Acquired by Scancell in All-Stock Merger - Minichart
NEUP Q4'26 Earnings: EPS estimate is (0.56) USD - TradingView
ACTU Stock Price and Chart — NASDAQ:ACTU - TradingView
Neuphoria Therapeutics Inc (NEUP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
NEUP Q2 2026 Earnings: Narrower-Than-Expected Loss Delivers 90.9% EPS SurpriseGeographic Revenue Trends - vinanet.vn
Neuphoria Therapeutics (NEUP) Pulls Back to $3.82 as Traders Eye Key Support ZoneForce Index - dars.gov.et
Neuphoria Therapeutics (NEUP) Pulls Back 1.27% to $3.9, Holds Above Key SupportSocial Sentiment - vinanet.vn
Are CBZ, SAFT, NEUP, TCBK Obtaining Fair Deals for their Shareholders? - tradingview.com
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
CNSY Stock Price and Chart — NASDAQ:CNSY - tradingview.com
Neuphoria Therapeutics (NEUP) Slips to $3.88 as Bulls Defend Key SupportSector ETF Flow - dars.gov.et
NEUP Q2 2026 Earnings: Narrower-Than-Expected Loss Signals Lean Cost ManagementEarnings Decline Risk - dars.gov.et
NEUP Q2 2026 Earnings: Narrower-Than-Expected Loss Signals Lean Cost ManagementGuidance vs Actual - vinanet.vn
NEUP Q2 2026 Earnings: Narrower-than-Expected Loss Delivers 90.9% EPS Surprise Amid Stock PullbackEarnings Weakness Phase - Vinanet
Scancell merges with Nasdaq shell Neuphoria to fund USD 89m Phase III melanoma trial - allsci.com
Neuphoria Therapeutics (NEUP) Gains 3.55% as Stock Tests Key Resistance Near $4.14Opening Range Breakout - careplusvn.com
Neuphoria Therapeutics (NEUP) Gains 3.55% as Stock Tests Key Resistance Near $4.14Volume Weighted Price - vinanet.vn
Neuphoria Therapeutics (NEUP) Gains 3.55% as Stock Tests Key Resistance Near $4.14Retail Driven Moves - dars.gov.et
Neuphoria Therapeutics (NEUP) Gains 3.55% as Stock Tests Key Resistance Near $4.14Trade Entry Signals - dars.gov.et
Advising Nasdaq-listed Neuphoria Therapeutics Inc. On Its USD250M Merger With AIM-listed Scancell Holdings - Mondaq
Neuphoria Therapeutics Inc. (NEUP) Q2 2026 Earnings: Loss Narrows Sharply, Exceeding ExpectationsEarnings Call Q&A - careplusvn.com
Neuphoria Therapeutics Inc. (NEUP) Q2 2026 Earnings: Loss Narrows Sharply, Exceeding ExpectationsEarnings Risk Report - vinanet.vn
Melanoma Biotech Secures Nasdaq Listing via All-Share Merger - Streetwise Reports
Advising Nasdaq-listed Neuphoria Therapeutics Inc. on its USD250M merger with AIM-listed Scancell Holdings - Winston Taylor
Halper Sadeh LLC is Investigating Whether SAFT, NEUP, NRIM are Obtaining Fair Deals for their Shareholders - GlobeNewswire
Mintz Advises on $39 Million Private Placement Concurrent with Scancell Holdings and Neuphoria Therapeutics’ Merger Transaction - Mintz
Neuphoria Therapeutics Inc (NEUP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Neuphoria Therapeutics Inc (NEUP) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Neuphoria Therapeutics Inc (NASDAQ: NEUP) Share Price, NEUP Stock News, NEUP Share Price & Updates - Kalkine
Neuphoria Therapeutics Inc (NEUP) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Neuphoria Therapeutics Inc (NEUP) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Neuphoria Therapeutics Inc (NEUP) Income Statement - tradingkey.com
Neuphoria Therapeutics (NEUP) Drops 7%: Key Levels in Focus After Sharp DeclineFibonacci Time Zone - po-news-eg.net
Neuphoria Therapeutics Inc. Revenue Breakdown – NASDAQ:NEUP - TradingView
NEUP|Neuphoria Therapeutics Inc|Price:3.810|Chg%:+0.170 - TradingKey
Neuphoria Therapeutics Inc (NEUP) Cash Flow - TradingKey
Neuphoria Therapeutics (NEUP) Drops 7%: Key Levels in Focus After Sharp DeclineWave Equality - careplusvn.com
Neuphoria Therapeutics (NEUP) Drops 7%: Key Levels in Focus After Sharp DeclineShort Term Trading Ideas - vinanet.vn
Neuphoria Therapeutics Market Sentiment - Benzinga España
NEUP|Neuphoria Therapeutics Inc|Price:3.810|Chg%:+0.170 - TradingKey
NEUP|Neuphoria Therapeutics Inc|Price:3.970|Chg%:+0.330 - TradingKey
Neuphoria Therapeutics Inc (NASDAQ: NEUP) Share Price, NEUP Stock News, NEUP Share Price & Updates - kalkine.ca
NEUP Stock Alert: Halper Sadeh LLC is Investigating Whether Neuphoria Therapeutics Inc. is Obtaining a Fair Price for its Shareholders - Business Wire
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Neuphoria Therapeutics, Inc. (NASDAQ: NEUP) - Morningstar
Monteverde & Associates investigates Neuphoria Therapeutics merger fairness for shareholders. - Pluang
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Neuphoria Therapeutics, Inc. (NASDAQ: NEUP) - PR Newswire
Neuphoria Therapeutics (NEUP) Proxy filing Summary - Quartr
Neuphoria Therapeutics to Merge with Scancell Holdings - TipRanks
Neuphoria Therapeutics (Nasdaq: NEUP) to be acquired by Scancell - Stock Titan
Neuphoria Therapeutics Inc Stock (NEUP) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):